Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep;85(5):747–751. doi: 10.1054/bjoc.2001.1966

Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II α gene transfer is independent of topoisomerase II β

Z Zhou 1, L A Zwelling 3, R Ganapathi 4, E S Kleinerman 2
PMCID: PMC2364113  PMID: 11531262

Abstract

The roles that the α and β isoforms of topoisomerase II (topo II) play in anticancer drug action were determined using MDA-VP etoposide-resistant human breast cancer cells and a newly constructed adenoviral vector containing the topo IIα gene (Ad-topo IIα). MDA-VP cells were more resistant to etoposide than to amsacrine and had more resistance to etoposide than did MDA-parental cells. MDA-VP cells also expressed lower topo IIα RNA and protein levels than parental cells but had comparable topo IIβ levels. After infection with Ad-topo IIα, topo IIα, RNA and protein levels increased significantly, as did the cells' sensitivity to etoposide. In contrast, topo IIβ levels remained constant with little alteration in the cells' sensitivity to amsacrine. Band-depletion immunoblotting assays indicated that topo IIα was depleted in etoposide-treated, Ad-topo IIα-transduced MDA-VP cells but not in amsacrine-treated cells. Topo IIβ was depleted in amsacrine-treated, Ad-topo IIα-MDA-VP cells, with little change in the topo IIα levels. These results suggest that topo IIα gene transfer does not alter topo IIβ expression and that enhanced sensitivity to etoposide is therefore secondary to change in topo IIα levels. These studies support the theory that etoposide preferentially targets topo IIα, while amsacrine targets topo IIβ. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: topoisomerase IIα, topoisomerase IIβ, etoposide, amsacrine, drug targetting

Full Text

The Full Text of this article is available as a PDF (147.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asano T., An T., Mayes J., Zwelling L. A., Kleinerman E. S. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J. 1996 Oct 1;319(Pt 1):307–313. doi: 10.1042/bj3190307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Asano T., An T., Zwelling L. A., Takano H., Fojo A. T., Kleinerman E. S. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Oncol Res. 1996;8(3):101–110. [PubMed] [Google Scholar]
  3. Austin C. A., Marsh K. L. Eukaryotic DNA topoisomerase II beta. Bioessays. 1998 Mar;20(3):215–226. doi: 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  4. Austin C. A., Sng J. H., Patel S., Fisher L. M. Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta. 1993 Mar 20;1172(3):283–291. doi: 10.1016/0167-4781(93)90215-y. [DOI] [PubMed] [Google Scholar]
  5. Dereuddre S., Delaporte C., Jacquemin-Sablon A. Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res. 1997 Oct 1;57(19):4301–4308. [PubMed] [Google Scholar]
  6. Errington F., Willmore E., Tilby M. J., Li L., Li G., Li W., Baguley B. C., Austin C. A. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol. 1999 Dec;56(6):1309–1316. doi: 10.1124/mol.56.6.1309. [DOI] [PubMed] [Google Scholar]
  7. Ganapathi R., Constantinou A., Kamath N., Dubyak G., Grabowski D., Krivacic K. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Mol Pharmacol. 1996 Aug;50(2):243–248. [PubMed] [Google Scholar]
  8. Herzog C. E., Holmes K. A., Tuschong L. M., Ganapathi R., Zwelling L. A. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha. Cancer Res. 1998 Dec 1;58(23):5298–5300. [PubMed] [Google Scholar]
  9. Jenkins J. R., Ayton P., Jones T., Davies S. L., Simmons D. L., Harris A. L., Sheer D., Hickson I. D. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 1992 Nov 11;20(21):5587–5592. doi: 10.1093/nar/20.21.5587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Koo H. M., Gray-Goodrich M., Kohlhagen G., McWilliams M. J., Jeffers M., Vaigro-Wolff A., Alvord W. G., Monks A., Paull K. D., Pommier Y. The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. J Natl Cancer Inst. 1999 Feb 3;91(3):236–244. doi: 10.1093/jnci/91.3.236. [DOI] [PubMed] [Google Scholar]
  11. Malonne H., Atassi G. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs. 1997 Oct;8(9):811–822. doi: 10.1097/00001813-199710000-00001. [DOI] [PubMed] [Google Scholar]
  12. Matsumoto Y., Takano H., Fojo T. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res. 1997 Nov 15;57(22):5086–5092. [PubMed] [Google Scholar]
  13. Tan K. B., Dorman T. E., Falls K. M., Chung T. D., Mirabelli C. K., Crooke S. T., Mao J. Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res. 1992 Jan 1;52(1):231–234. [PubMed] [Google Scholar]
  14. Tsai-Pflugfelder M., Liu L. F., Liu A. A., Tewey K. M., Whang-Peng J., Knutsen T., Huebner K., Croce C. M., Wang J. C. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7177–7181. doi: 10.1073/pnas.85.19.7177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Turley H., Comley M., Houlbrook S., Nozaki N., Kikuchi A., Hickson I. D., Gatter K., Harris A. L. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer. 1997;75(9):1340–1346. doi: 10.1038/bjc.1997.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wang J. C. DNA topoisomerases. Annu Rev Biochem. 1996;65:635–692. doi: 10.1146/annurev.bi.65.070196.003223. [DOI] [PubMed] [Google Scholar]
  17. Withoff S., de Vries E. G., Keith W. N., Nienhuis E. F., van der Graaf W. T., Uges D. R., Mulder N. H. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer. 1996 Dec;74(12):1869–1876. doi: 10.1038/bjc.1996.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Yang X., Li W., Prescott E. D., Burden S. J., Wang J. C. DNA topoisomerase IIbeta and neural development. Science. 2000 Jan 7;287(5450):131–134. doi: 10.1126/science.287.5450.131. [DOI] [PubMed] [Google Scholar]
  19. Zwelling L. A., Hinds M., Chan D., Mayes J., Sie K. L., Parker E., Silberman L., Radcliffe A., Beran M., Blick M. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem. 1989 Oct 5;264(28):16411–16420. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES